XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.21.2

REVENUES - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 7,421 | $ 6,577 | $ 20,061 | $ 17,268
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5,509 | 5,100 | 14,002 | 12,890
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,031 | 937 | 3,559 | 2,698
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 881 | 540 | 2,500 | 1,680
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7,356 | 6,493 | 19,848 | 17,027
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5,479 | 5,076 | 13,932 | 12,835
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 997 | 877 | 3,419 | 2,528
Total product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 880 | 540 | 2,497 | 1,664
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,189 | 4,547 | 11,777 | 12,681
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,302 | 3,722 | 9,132 | 10,213
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 602 | 569 | 1,776 | 1,720
Total HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 285 | 256 | 869 | 748
Atripla |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 27 | 113 | 118 | 311
Atripla | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 21 | 99 | 96 | 275
Atripla | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2 | 5 | 10 | 17
Atripla | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 9 | 12 | 19
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,276 | 1,891 | 6,094 | 5,188
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,875 | 1,584 | 4,926 | 4,346
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 254 | 194 | 707 | 528
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 147 | 113 | 461 | 314
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 64 | 70 | 189 | 218
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 26 | 73 | 77
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 31 | 35 | 104 | 124
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 9 | 12 | 17
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 433 | 508 | 1,227 | 1,383
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 355 | 424 | 994 | 1,124
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 42 | 49 | 128 | 156
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 36 | 35 | 105 | 103
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 744 | 846 | 2,123 | 2,486
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 576 | 669 | 1,633 | 1,927
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 100 | 116 | 306 | 376
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 68 | 61 | 184 | 183
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 399 | 437 | 1,148 | 1,228
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 275 | 309 | 773 | 851
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 112 | 116 | 336 | 341
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 12 | 39 | 36
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 42 | 42 | 139 | 154
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 27 | 94 | 100
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 11 | 13 | 33 | 42
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 2 | 12 | 12
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 67 | 509 | 310 | 1,302
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 55 | 492 | 268 | 1,245
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 6 | 18 | 20
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 11 | 24 | 37
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 130 | 118 | 394 | 362
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 86 | 82 | 261 | 244
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 41 | 34 | 125 | 112
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 2 | 8 | 6
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 13 | 35 | 49
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 10 | 14 | 24
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4 | 1 | 9 | 4
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 2 | 12 | 21
Total HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 429 | 464 | 1,488 | 1,641
Total HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 224 | 241 | 809 | 859
Total HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 94 | 98 | 322 | 316
Total HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 111 | 125 | 357 | 466
Ledipasvir/Sofosbuvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 45 | 84 | 163 | 263
Ledipasvir/Sofosbuvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 14 | 36 | 63 | 113
Ledipasvir/Sofosbuvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 11 | 24 | 26
Ledipasvir/Sofosbuvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 37 | 76 | 124
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 332 | 330 | 1,155 | 1,229
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 173 | 170 | 649 | 646
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 77 | 74 | 234 | 253
Sofosbuvir/Velpatasvir | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 82 | 86 | 272 | 330
Other HCV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 52 | 50 | 170 | 149
Other HCV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 37 | 35 | 97 | 100
Other HCV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 13 | 64 | 37
Other HCV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 2 | 9 | 12
Total HBV/HDV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 247 | 211 | 704 | 616
Total HBV/HDV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 104 | 102 | 275 | 267
Total HBV/HDV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 29 | 18 | 76 | 55
Total HBV/HDV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 114 | 91 | 353 | 294
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 208 | 177 | 589 | 464
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 103 | 99 | 266 | 248
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 8 | 25 | 22
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 96 | 70 | 298 | 194
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 32 | 85 | 137
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1 | 3 | 8 | 10
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 8 | 22 | 27
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 18 | 21 | 55 | 100
Other HBV/HBD |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 2 | 30 | 15
Other HBV/HBD | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 1 | 9
Other HBV/HBD | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 2 | 29 | 6
Other HBV/HBD | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,923 | 873 | 4,208 | 873
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,527 | 785 | 2,763 | 785
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 109 | 60 | 761 | 60
Veklury | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 287 | 28 | 684 | 28
Total Cell Therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 222 | 147 | 632 | 444
Total Cell Therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 135 | 90 | 394 | 288
Total Cell Therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 78 | 55 | 213 | 149
Total Cell Therapy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 2 | 25 | 7
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 47 | 9 | 119 | 10
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 35 | 5 | 94 | 5
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 12 | 4 | 25 | 5
Tecartus | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 175 | 138 | 513 | 434
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 100 | 85 | 300 | 283
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 66 | 51 | 188 | 144
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 9 | 2 | 25 | 7
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 101 | 0 | 262 | 0
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 100 | 0 | 261 | 0
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1 | 0 | 1 | 0
Trodelvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Total Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 245 | 251 | 777 | 772
Total Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 87 | 136 | 298 | 423
Total Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 84 | 77 | 270 | 228
Total Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 74 | 38 | 209 | 121
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 143 | 111 | 420 | 325
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 18 | 32 | 46
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 67 | 58 | 202 | 166
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 69 | 35 | 186 | 113
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 46 | 78 | 157 | 241
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 46 | 78 | 157 | 241
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 0 | 0
Ranexa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues |  |  | 5 | 9
Ranexa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues |  |  | 5 | 9
Ranexa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues |  |  | 0 | 0
Ranexa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues |  |  | 0 | 0
Zydelig |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 13 | 17 | 50 | 55
Zydelig | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6 | 8 | 22 | 24
Zydelig | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 9 | 27 | 30
Zydelig | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 0 | 0 | 1 | 1
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 43 | 45 | 145 | 142
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 28 | 32 | 82 | 103
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 10 | 41 | 32
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 5 | 3 | 22 | 7
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 84 | 213 | 241
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 30 | 24 | 70 | 55
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 60 | 140 | 170
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 1 | $ 0 | $ 3 | $ 16

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherHepatitisCVirusProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HepatitisBVirusHepatitisDeltaVirusProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |